The European Union is investing €225 million to expedite the development of next-generation influenza vaccines. These vaccines are intended to offer protection against a broader range of influenza variants and can be rapidly adapted to emerging pandemic strains.
This initiative marks the first time the European Commission will use pre-commercial procurement to advance products through clinical trials, ensuring they meet rigorous safety, quality, and efficacy standards while supporting innovations that may not progress without public intervention.
The funding will facilitate the development of vaccines that can be administered more easily via the nose, mouth, or skin patches and that can be quickly scaled up during emergencies. Given the constant evolution of flu viruses, vaccine technology must keep pace with this change. This investment aims to accelerate vaccine development and enhance Europe’s capacity to respond effectively to public health challenges.
“With an EU investment of €225 million – the largest ever dedicated to accelerating access to innovative medical countermeasures – we are advancing the development of next-generation flu vaccines. Innovation is at the heart of preparedness,” stated Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management. “This funding will unlock cutting-edge technologies, including more accessible and diverse vaccine administration methods, ensuring that effective vaccine options reach underserved and vulnerable groups. This investment also strengthens Europe’s pharmaceutical ecosystem, contributing to its competitiveness, and reinforces our resilience against future health threats,” the commissioner added.
Through the comprehensive clinical development of promising vaccine candidates, the EU seeks to broaden the pipeline of available products. This expansion increases the likelihood that novel vaccines will reach the market, transitioning from laboratory innovations to practical applications. As a result, new solutions can be integrated into national vaccination programs more rapidly, allowing countries to respond with greater efficiency and coordination when faced with intensifying outbreaks.
The contracts established will be effective for 98 months, covering the entire process from clinical development to market authorisation. By expanding vaccine production capabilities and introducing novel treatment options, this investment will bolster both Europe’s and the global community’s readiness for future influenza outbreaks or pandemics.
This investment is financed by the EU4Health programme and managed by the European Health and Digital Executive Agency, with contracts awarded to organisations such as Nivi Development and Sanofi Pasteur.
